|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anderson WF, Katki HA and Rosenberg PS:
Incidence of breast cancer in the United States: Current and future
trends. J Natl Cancer Inst. 103:1397–1402. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marshall E: Breast cancer. Dare to do less
Science. 343:1454–1456. 2014.
|
|
4
|
Vargo-Gogola T and Rosen JM: Modelling
breast cancer: One size does not fit all. Nat Rev Cancer.
7:659–672. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Green KA and Carroll JS:
Oestrogen-receptor-mediated transcription and the influence of
co-factors and chromatin state. Nat Rev Cancer. 7:713–722. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Musgrove EA and Sutherland RL: Biological
determinants of endocrine resistance in breast cancer. Nat Rev
Cancer. 9:631–643. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Patani N and Martin LA: Understanding
response and resistance to oestrogen deprivation in ER-positive
breast cancer. Mol Cell Endocrinol. 382:683–694. 2014. View Article : Google Scholar
|
|
8
|
Cuzick J, Sestak I, Pinder SE, Ellis IO,
Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS and George
WD: Effect of tamoxifen and radiotherapy in women with locally
excised ductal carcinoma in situ: Long-term results from the UK/ANZ
DCIS trial. Lancet Oncol. 12:21–29. 2011. View Article : Google Scholar :
|
|
9
|
Jordan VC: Tamoxifen as the first targeted
long-term adjuvant therapy for breast cancer. Endocr Relat Cancer.
21:R235–R246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Briest S and Stearns V: Tamoxifen
metabolism and its effect on endocrine treatment of breast cancer.
Clin Adv Hematol Oncol. 7:185–192. 2009.PubMed/NCBI
|
|
11
|
Lønning PE: Adjuvant endocrine treatment
of early breast cancer. Hematol Oncol Clin North Am. 21:223–238.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arimidex, Tamoxifen, Alone or in
Combination (ATAC) Trialists' Group; Forbes JF, Cuzick J, Buzdar A,
Howell A, Tobias JS and Baum M: Effect of anastrozole and tamoxifen
as adjuvant treatment for early-stage breast cancer: 100-month
analysis of the ATAC trial. Lancet Oncol. 9:45–53. 2008. View Article : Google Scholar
|
|
13
|
Raha P, Thomas S and Munster PN:
Epigenetic modulation: A novel therapeutic target for overcoming
hormonal therapy resistance. Epigenomics. 3:451–470. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thewes V, Simon R, Schroeter P, Schlotter
M, Anzeneder T, Büttner R, Benes V, Sauter G, Burwinkel B,
Nicholson RI, et al: Reprogramming of the ERRalpha and ERalpha
target gene landscape triggers tamoxifen resistance in breast
cancer. Cancer Res. 75:720–731. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baneshi MR, Warner P, Anderson N, Edwards
J, Cooke TG and Bartlett JM: Tamoxifen resistance in early breast
cancer: Statistical modelling of tissue markers to improve risk
prediction. Br J Cancer. 102:1503–1510. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baselga J, Campone M, Piccart M, Burris HA
III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun
F, et al: Everolimus in postmenopausal hormone-receptor-positive
advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar
|
|
17
|
Turner NC, Ro J, André F, Loi S, Verma S,
Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, et al:
Palbociclib in hormone-receptor-positive advanced breast cancer. N
Engl J Med. 373:209–219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zagouri F, Liakou P, Bartsch R, Peccatori
FA, Tsigginou A, Dimitrakakis C, Zografos GC, Dimopoulos MA and
Azim HA Jr: Discrepancies between ESMO and NCCN breast cancer
guidelines: An appraisal. Breast. 24:513–523. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yuan J, Liu M, Yang L, Tu G, Zhu Q, Chen
M, Cheng H, Luo H, Fu W, Li Z and Yang G: Acquisition of
epithelial-mesenchymal transition phenotype in the
tamoxifen-resistant breast cancer cell: A new role for G
protein-coupled estrogen receptor in mediating tamoxifen resistance
through cancer-associated fibroblast-derived fibronectin and
β1-integrin signaling pathway in tumor cells. Breast Cancer Res.
17:692015. View Article : Google Scholar
|
|
20
|
Bui QT, Im JH, Jeong SB, Kim YM, Lim SC,
Kim B and Kang KW: Essential role of Notch4/STAT3 signaling in
epithelial-mesenchymal transition of tamoxifen-resistant human
breast cancer. Cancer Lett. 390:115–125. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ward A, Balwierz A, Zhang JD, Küblbeck M,
Pawitan Y, Hielscher T, Wiemann S and Sahin Ö: Re-expression of
microRNA-375 reverses both tamoxifen resistance and accompanying
EMT-like properties in breast cancer. Oncogene. 32:1173–1182. 2013.
View Article : Google Scholar
|
|
22
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fallah Y, Brundage J, Allegakoen P and
Shajahan-Haq AN: MYC-driven pathways in breast cancer subtypes.
Biomolecules. 7:E532017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Raha P, Thomas S, Thurn KT, Park J and
Munster PN: Combined histone deacetylase inhibition and tamoxifen
induces apoptosis in tamoxifen-resistant breast cancer models, by
reversing Bcl-2 overexpression. Breast Cancer Res. 17:262015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qi H, Jiang Z, Wang C, Yang Y, Li L, He H
and Yu Z: Sensitization of tamoxifen-resistant breast cancer cells
by Z-ligustilide through inhibiting autophagy and accumulating DNA
damages. Oncotarget. 8:29300–29317. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sebaugh JL: Guidelines for accurate
EC50/IC50 estimation. Pharm Stat. 10:128–134.
2011. View Article : Google Scholar
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
28
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar
|
|
29
|
Yuan JQ, Wang SM, Tang LL, Mao J, Wu YH,
Hai J, Luo SY, Ou HY, Guo L, Liao LQ, et al: Relative dose
intensity and therapy efficacy in different breast cancer molecular
subtypes: A retrospective study of early stage breast cancer
patients treated with neoadjuvant chemotherapy. Breast Cancer Res
Treat. 151:405–413. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han C, Yang L, Choi HH, Baddour J, Achreja
A, Liu Y, Li Y, Li J, Wan G, Huang C, et al: Amplification of USP13
drives ovarian cancer metabolism. Nat Commun. 7:135252016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lindström LS, Karlsson E, Wilking UM,
Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L and Bergh
J: Clinically used breast cancer markers such as estrogen receptor,
progesterone receptor, and human epidermal growth factor receptor 2
are unstable throughout tumor progression. J Clin Oncol.
30:2601–2608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cui J, Germer K, Wu T, Wang J, Luo J, Wang
SC, Wang Q and Zhang X: Cross-talk between HER2 and MED1 regulates
tamoxifen resistance of human breast cancer cells. Cancer Res.
72:5625–5634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gonzalez-Malerva L, Park J, Zou L, Hu Y,
Moradpour Z, Pearlberg J, Sawyer J, Stevens H, Harlow E and LaBaer
J: High-throughput ectopic expression screen for tamoxifen
resistance identifies an atypical kinase that blocks autophagy.
Proc Natl Acad Sci USA. 108:2058–2063. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng R, Liu YJ, Cui JW, Yang M, Liu XL,
Li P, Wang Z, Zhu LZ, Lu SY, Zou L, et al: Aspirin regulation of
c-myc and cyclinD1 proteins to overcome tamoxifen resistance in
estrogen receptor-positive breast cancer cells. Oncotarget.
8:30252–30264. 2017.PubMed/NCBI
|
|
35
|
Cheng AS, Jin VX, Fan M, Smith LT,
Liyanarachchi S, Yan PS, Leu YW, Chan MW, Plass C, Nephew KP, et
al: Combinatorial analysis of transcription factor partners reveals
recruitment of c-MYC to estrogen receptor-alpha responsive
promoters. Mol Cell. 21:393–404. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Musgrove EA, Sergio CM, Loi S, Inman CK,
Anderson LR, Alles MC, Pinese M, Caldon CE, Schütte J,
Gardiner-Garden M, et al: Identification of functional networks of
estrogen- and c-Myc-responsive genes and their relationship to
response to tamoxifen therapy in breast cancer. PLoS One.
3:e29872008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cepeda V, Fuertes MA, Castilla J, Alonso
C, Quevedo C and Pérez JM: Biochemical mechanisms of cisplatin
cytotoxicity. Anticancer Agents Med Chem. 7:3–18. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dobbelstein M and Sørensen CS: Exploiting
replicative stress to treat cancer. Nat Rev Drug Discov.
14:405–423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
|
|
40
|
Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang
Y, Jia L, Li S; Cancer Genome Atlas Research Network; Xie W and
Yang D: lncRNA epigenetic landscape analysis identifies EPIC1 as an
oncogenic lncRNA that interacts with MYC and promotes cell-cycle
progression in cancer. Cancer Cell. 33:706–720.e9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Meyer N and Penn LZ: Reflecting on 25
years with MYC. Nat Rev Cancer. 8:976–990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Graham J, Pitz M, Gordon V, Grenier D,
Amir E and Niraula S: Clinical predictors of benefit from
fulvestrant in advanced breast cancer: A Meta-analysis of
randomized controlled trials. Cancer Treat Rev. 45:1–6. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ma CX, Reinert T, Chmielewska I and Ellis
MJ: Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer.
15:261–275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Coates AS, Winer EP, Goldhirsch A, Gelber
RD, Gnant M, Piccart-Gebhart M, Thürlimann B and Senn HJ: Tailoring
therapies-improving the management of early breast cancer: St
Gallen International Expert Consensus on the primary therapy of
early breast cancer 2015. Ann Oncol. 26:1533–1546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
van Agthoven T, Sieuwerts AM, Meijer-van
Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA
and Dorssers LC: Relevance of breast cancer antiestrogen resistance
genes in human breast cancer progression and tamoxifen resistance.
J Clin Oncol. 27:542–549. 2009. View Article : Google Scholar
|
|
46
|
Cardoso F, Costa A, Senkus E, Aapro M,
André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso
MJ, et al: 3rd ESO-ESMO International Consensus Guidelines for
advanced breast cancer (ABC 3). Ann Oncol. 28:31112017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jeselsohn R, Buchwalter G, De Angelis C,
Brown M and Schiff R: ESR1 mutations-a mechanism for acquired
endocrine resistance in breast cancer. Nat Rev Clin Oncol.
12:573–583. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Osborne CK and Schiff R: Mechanisms of
endocrine resistance in breast cancer. Annu Rev Med. 62:233–247.
2011. View Article : Google Scholar
|
|
49
|
Lin CY, Lovén J, Rahl PB, Paranal RM,
Burge CB, Bradner JE, Lee TI and Young RA: Transcriptional
amplification in tumor cells with elevated c-Myc. Cell. 151:56–67.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jin K, Park S, Teo WW, Korangath P, Cho
SS, Yoshida T, Győrffy B, Goswami CP, Nakshatri H, Cruz LA, et al:
HOXB7 is an ERα cofactor in the activation of HER2 and multiple ER
target genes leading to endocrine resistance. Cancer Discov.
5:944–959. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Manso L, Mourón S, Tress M, Gómez-López G,
Morente M, Ciruelos E, Rubio-Camarillo M, Rodriguez-Peralto JL,
Pujana MA, Pisano DG and Quintela-Fandino M: Analysis of paired
primary-metastatic hormone-receptor positive breast tumors (HRPBC)
uncovers potential novel drivers of hormonal resistance. PLoS One.
11:pp. e01558402016, View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Miller TW, Balko JM, Ghazoui Z, Dunbier A,
Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu
H, et al: A gene expression signature from human breast cancer
cells with acquired hormone independence identifies MYC as a
mediator of antiestrogen resistance. Clin Cancer Res. 17:2024–2034.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yin S, Rishi AK and Reddy KB:
Anti-estrogenresistant breast cancer cells are sensitive to
cisplatin plus TRAIL treatment. Oncol Rep. 33:1475–1480. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yde CW, Gyrd-Hansen M, Lykkesfeldt AE,
Issinger OG and Stenvang J: Breast cancer cells with acquired
antiestrogen resistance are sensitized to cisplatin-induced cell
death. Mol Cancer Ther. 6:1869–1876. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Leung EY, Kim JE, Askarian-Amiri M, Joseph
WR, McKeage MJ and Baguley BC: Hormone resistance in Two MCF-7
breast cancer cell lines is associated with reduced mTOR signaling,
decreased glycolysis, and increased sensitivity to cytotoxic drugs.
Front Oncol. 4:2212014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhu H, Wu J, Zhang W, Luo H, Shen Z, Cheng
H and Zhu X: PKM2 enhances chemosensitivity to cisplatin through
interaction with the mTOR pathway in cervical cancer. Sci Rep.
6:307882016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Gao T, Han Y, Yu L, Ao S, Li Z and Ji J:
CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen
resistance. PLoS One. 9:pp. e917712014, View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gao A, Sun T, Ma G, Cao J, Hu Q, Chen L,
Wang Y, Wang Q, Sun J, Wu R, et al: LEM4 confers tamoxifen
resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb
and ERα pathway. Nat Commun. 9:41802018. View Article : Google Scholar
|
|
60
|
Kangaspeska S, Hultsch S, Jaiswal A,
Edgren H, Mpindi JP, Eldfors S, Brück O, Aittokallio T and
Kallioniemi O: Systematic drug screening reveals specific
vulnerabilities and co-resistance patterns in endocrine-resistant
breast cancer. BMC Cancer. 16:3782016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Jiang D, Sui M, Zhong W, Huang Y and Fan
W: Different administration strategies with paclitaxel induce
distinct phenotypes of multidrug resistance in breast cancer cells.
Cancer Lett. 335:404–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Baekelandt MM, Holm R, Nesland JM, Tropé
CG and Kristensen GB: P-glycoprotein expression is a marker for
chemotherapy resistance and prognosis in advanced ovarian cancer.
Anticancer Res. 20:1061–1067. 2000.PubMed/NCBI
|
|
63
|
Wada H, Saikawa Y, Niida Y, Nishimura R,
Noguchi T, Matsukawa H, Ichihara T and Koizumi S: Selectively
induced high MRP gene expression in multidrug-resistant human HL60
leukemia cells. Exp Hematol. 27:99–109. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Jacobsen C and Honecker F: Cisplatin
resistance in germ cell tumours: Models and mechanisms. Andrology.
3:111–121. 2015. View Article : Google Scholar
|
|
65
|
Beuvink I, Boulay A, Fumagalli S,
Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA and
Thomas G: The mTOR inhibitor RAD001 sensitizes tumor cells to
DNA-damaged induced apoptosis through inhibition of p21
translation. Cell. 120:747–759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhu Y, Liu Y, Zhang C, Chu J, Wu Y, Li Y,
Liu J, Li Q, Li S, Shi Q, et al: Tamoxifen-resistant breast cancer
cells are resistant to DNA-damaging chemotherapy because of
upregulated BARD1 and BRCA1. Nat Commun. 9:15952018. View Article : Google Scholar : PubMed/NCBI
|
